Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR [Yahoo! Finance]
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $179.00 to $177.00. They now have an "overweight" rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $172.00 to $169.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $175.00 price target on the stock, up previously from $173.00.